Research and Resources

/Research and Resources
Research and Resources2018-11-15T13:52:04+00:00

To improve the outcomes in IBC, a wide spectrum of research is being performed both in the lab and the clinic.  Since it may not be easy to find this research, we’ve decided to pull together the most recent information that may be of interest to physicians and researchers in the field.  For papers below that are behind a firewall, if you wish to access the full text and do not have an institutional/personal subscription, please contact us at hello@theibcnetwork.org and we’d be happy to send you the PDF for your personal use.

Enrolling Clinical Trials

To download a PDF file containing the IBC-focused clinical trials, click HERE.

Published Clinical Trial Results and General Medical Articles

While there are not a large number of IBC focused trials that have been completed, the modern ones (2000-onwards) that have influenced the current standard of care are listed below. Not all of these are exclusive to IBC.

Systemic Therapy:

HER2+ breast cancer (40% of IBC):

Gianni L et al, “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial” Lancet Onc 2012 

Gianni L et al, “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.” Lancet Onc 2016 

Von Minckwitz G et al,  “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.” NEJM 2017 **

** Study not focused on IBC however applies to IBC due to high-risk patients benefiting from therapy.

ER+ and TN-IBC:

Matsuda N et al “Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer” JAMA Oncology 2018 

Masuda N et al, “Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.” NEJM 2017 **

** Study not focused on IBC however applies to IBC due to high-risk patients benefiting from therapy

Surgical studies:

Stearns V et al, “Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.” Ann Surg Oncol 2002

DeSnyder SM et al, “Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.” Clin Breast Cancer 2018 

General Summary Articles:

Ueno NT et al, “International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference” J Cancer 2018

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA. et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 

IBC Imaging Articles:

Yang WT et al. “Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings”. Breast Cancer Res Treat. 2008 

Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C. et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013